Genprex Gapping on Non-Human Primate Type 1 Diabetes study data

(24/7 MARKET NEWS) – Genprex, Inc. (NASDAQ: GNPX) announced, this morning, that data highlighting the potential of its Type 1 diabetes gene therapy results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline. The data will be presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes taking place February 22-25, 2023 in Berlin, Germany.

Genprex is at $1.70, up $0.06 (+3.66%), on trading volume of 2.6 million premarket shares.

Its 52-week trading range is $0.97 to $2.67. It popped and hit $2.14 just after this morning’s announcement, but it pulled back and its next key inflection point is $1.79.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist